Trupanion, Inc. — Q1 2022 Form 10-Q Summary
Business context and reporting period
Trupanion provides medical insurance for cats and dogs in the United States, Canada, Puerto Rico, and Australia. The filing reports unaudited results for the three months ended March 31, 2022, compared with the three months ended March 31, 2021. The company operates through subscription and other business segments.
Financial performance and key metrics
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Revenue | $206.0 million | $154.7 million | Up 33% |
| Gross profit | $29.9 million | $21.1 million | Up 42% |
| Gross margin | 14.5% | 13.7% | Up approximately 80 bps |
| Operating loss | $9.1 million | $12.7 million | Improved $3.6 million |
| Operating margin | (4.4%) | (8.2%) | Improved |
| Net loss | $8.9 million | $12.4 million | Improved $3.6 million |
| Net loss per share | $0.22 | $0.31 | Improved |
| Cash used in operating activities | $3.6 million | $1.7 million | Higher use of cash |
| Capital expenditures | $3.6 million | $2.9 million | Higher |
Subscription revenue increased 23% to $139.8 million, while other business revenue increased 60% to $66.2 million. Subscription pets enrolled rose 21% year over year to 736,691, and total pets enrolled increased 34% to 1,267,253. Monthly average revenue per subscription pet rose 2% to $64.21, and average monthly retention improved slightly to 98.75% from 98.73%.
Cost of revenue was $176.1 million, or 85% of revenue, compared with 86% in the prior-year quarter. Veterinary invoice expense was $144.9 million, including $100.6 million for the subscription segment and $44.3 million for the other business segment. New pet acquisition expense increased 10% to $21.6 million, while average pet acquisition cost increased 8% to $301.
Technology and development expense increased 40% to $5.2 million, and general and administrative expense increased 30% to $9.4 million. Stock-based compensation expense declined to $7.5 million from $8.4 million, primarily because a prior-year performance grant had fully vested in Q1 2021.
Liquidity, cash flow, debt, and balance sheet
- Cash and cash equivalents were $122.5 million at March 31, 2022, compared with $87.4 million at December 31, 2021.
- Short-term investments were $136.6 million and long-term investments were $7.4 million. Cash, cash equivalents, and short-term investments totaled $259.0 million.
- Net cash used in operating activities was $3.6 million. Management attributed the use primarily to higher acquisition spending, faster payment of veterinary invoices, and timing differences in collections and payments.
- Net cash used in investing activities was $14.3 million, principally reflecting net investment purchases and capital expenditures.
- Net cash provided by financing activities was $52.8 million, primarily from the new term loan.
- On March 25, 2022, the company entered into a $150.0 million secured credit facility. It included a $60.0 million initial term loan, up to $75.0 million of delayed-draw term loans, and a $15.0 million revolving facility. Approximately $54.5 million of net proceeds were received after financing fees.
- Total debt carrying value at March 31, 2022 was $54.3 million, consisting of $0.6 million current debt and $53.7 million long-term debt. The interest rate was approximately 5.76% at quarter-end.
- Management stated that cash resources and available borrowings were sufficient to fund operations and regulatory capital requirements for the next 12 months. The company had $90.0 million of remaining availability under the credit facility.
Material changes versus the prior comparable period
- Revenue growth accelerated through both higher subscription enrollment and substantially higher other business enrollment.
- Losses narrowed despite continued investment in growth, with operating margin improving from negative 8.2% to negative 4.4%.
- Subscription cost of revenue as a percentage of subscription revenue improved from 84% to 82%; the other business segment remained at approximately 92% of segment revenue.
- Average pet acquisition cost increased from $279 to $301, although acquisition expense represented a smaller percentage of total revenue.
- The company raised debt financing for the first time reflected in the quarter-end balance sheet, increasing liquidity but also adding secured leverage and covenant obligations.
- Deferred revenue increased to $171.0 million from $146.9 million at year-end 2021, while accounts receivable increased to $189.0 million from $165.2 million.
Guidance, outlook, commentary, risks, and unusual items
The filing does not provide a clear numerical quarterly or full-year revenue or earnings guidance figure. Management expects to continue investing in pet acquisition, member experience, technology, new products, and international or adjacent opportunities. Management stated that COVID-19 had not materially adversely affected the business as of the filing date but emphasized that future effects remain uncertain.
- Veterinary invoice reserves totaled $38.5 million at March 31, 2022. Reserve adequacy depends on actuarial estimates and could materially affect future results if claims experience differs from assumptions.
- Insurance subsidiaries must maintain regulatory capital and surplus. Capital held in insurance entities may not be freely available for general corporate purposes, and required capital is expected to increase as enrollment grows.
- The credit facility is secured by substantially all company and subsidiary assets and contains financial and other covenants. The company reported compliance with all covenants at quarter-end.
- The other business segment generally has lower margins and depends on contracts with third parties that may be terminated. Loss of a program could materially reduce revenue over a 12- to 18-month period.
- Key risks include continued net losses, rising acquisition costs, retention and enrollment volatility, veterinary cost inflation, competition, regulatory approval of rates and products, foreign exchange exposure, cybersecurity and technology failures, litigation, and the ability to service debt.
- The company reported no material legal proceedings individually or in the aggregate at the time of filing, although ordinary-course litigation, coverage disputes, regulatory investigations, and other claims remain possible.
- The board-authorized share repurchase program remained unused. The company does not intend to pay cash dividends in the foreseeable future.
Important facts for investors to verify
- Whether subscription growth and retention remain sufficient to offset the increase in average pet acquisition cost.
- Whether subscription and other business loss ratios and veterinary invoice reserves develop as expected.
- Progress toward profitability and the sustainability of the improvement in gross and operating margins.
- Cash burn, capital requirements of insurance subsidiaries, and availability under the secured credit facility.
- Compliance with debt covenants and the impact of the approximately 5.76% variable interest rate.
- Exposure to third-party distribution relationships, especially in the other business segment and Canada.
- Regulatory approvals for pricing and product changes, as well as potential changes in insurance capital requirements.
- The effect of COVID-19, economic conditions, veterinary inflation, competition, and foreign exchange movements on enrollment, claims, retention, and liquidity.